JURA Bio
Creating a novel therapeutic platform of cell-based therapies against autoimmune diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | $16.1m | Seed | |
| Total Funding | 000k | ||
Related Content
JURA Bio, Inc. is pioneering the development of novel CAR T cell therapies aimed at combating autoimmune diseases, which affect over 20 million Americans. Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to significant health issues. JURA Bio's innovative therapeutic platform focuses on targeting and neutralizing these pathogenic immune cells, thereby interrupting the damaging cascade of events triggered by the immune system's malfunction.
The company operates in the biopharmaceutical sector, specifically within the niche of cellular medicine. Its primary clients include healthcare providers, research institutions, and potentially patients suffering from autoimmune conditions. JURA Bio's business model revolves around the research, development, and commercialization of its proprietary CAR T cell therapies. Revenue is generated through partnerships, licensing agreements, and eventually, the sale of its therapeutic products once they receive regulatory approval.
JURA Bio's approach is disruptive, leveraging the concept of immune synapses to precisely target and neutralize harmful cells. This method represents a significant advancement in the treatment of autoimmune diseases, offering hope for more effective and targeted therapies.
Keywords: CAR T cell therapies, autoimmune diseases, pathogenic immune cells, cellular medicine, biopharmaceutical, therapeutic platform, immune synapses, healthcare providers, research institutions, disruptive treatment.